What is the recommended treatment for Mycoplasma genitalium infection?

Treatment for Mycoplasma genitalium

For symptomatic M. genitalium infection, use sequential therapy with doxycycline 100 mg twice daily for 7 days followed by either azithromycin 500 mg on day 1, then 250 mg daily for days 2-5 (if macrolide-susceptible or resistance testing unavailable) OR moxifloxacin 400 mg daily for 7 days (if macrolide-resistant). 1, 2

Treatment Algorithm

First-Line: Sequential Two-Step Therapy

The modern approach prioritizes sequential therapy over single-agent treatment:

1. Start with doxycycline 100 mg orally twice daily for 7 days

   • Reduces organism load by 30-40%
   • Decreases risk of macrolide resistance selection
   • Does not induce resistance itself 1

2. Follow with resistance-guided therapy:

   • If macrolide-susceptible or testing unavailable: Azithromycin 500 mg on day 1, then 250 mg daily on days 2-5 1, 3
   • If macrolide-resistant: Moxifloxacin 400 mg daily for 7 days (uncomplicated) or 14 days (complicated infections like PID/epididymitis) 1, 2

The evidence strongly favors this sequential approach. A 2026 real-world cohort study demonstrated that doxycycline-quinolone sequential therapy had significantly lower treatment failure rates (aOR=0.36) and faster median clearance time (7 vs 10 weeks) compared to azithromycin monotherapy 4. The azithromycin-only group showed a concerning "long-tail" effect with mean clearance time of 94.2 weeks versus 28.0 weeks for sequential therapy 4.

Key Clinical Considerations

Macrolide resistance is now the dominant concern - more than 50% of M. genitalium infections are macrolide-resistant, making resistance-guided therapy essential when possible 5. However, macrolide resistance testing is not FDA-approved and remains largely unavailable in routine U.S. practice 2. When testing is unavailable, the sequential doxycycline-azithromycin approach is still recommended as first-line 2.

High-risk predictors for treatment failure:

• Chlamydia trachomatis co-infection (strongest predictor, aOR=3.21) 4
• Male sex 4
• These patients should be prioritized for sequential therapy with moxifloxacin rather than azithromycin

Second-Line Treatment

For persistent infection after first-line therapy or confirmed macrolide resistance:

• Moxifloxacin 400 mg daily for 7-10 days (uncomplicated infections) 1, 3
• Note: Fluoroquinolone resistance is increasing, limiting this option 5, 6

Third-Line Options for Refractory Cases

When both macrolides and fluoroquinolones fail:

• Doxycycline or minocycline 100 mg twice daily for 14 days - may cure 40-70% 1
• Pristinamycin 1 g four times daily for 10 days - approximately 75% cure rate 1
• High-dose tinidazole has shown success in case reports but lacks robust evidence 7

Complicated Infections (PID, Epididymitis)

Moxifloxacin 400 mg daily for 14 days is the preferred regimen 1, 3

Critical Pitfalls to Avoid

1. Do NOT use azithromycin 1 g single dose - this older regimen from 2010 guidelines 8 is now obsolete due to widespread macrolide resistance and has contributed to the resistance crisis 3

2. Do NOT screen or treat asymptomatic patients - testing should be limited to symptomatic individuals to avoid inappropriate antibiotic use and resistance development 5, 2

3. Do NOT perform routine test-of-cure in asymptomatic persons after treatment 5

4. Abstain from sexual activity for 7 days after single-dose therapy or until completion of multi-day regimens AND until all partners are treated 8

When to Test

Testing is indicated for:

• Persistent male urethritis (especially non-chlamydial, non-gonococcal)
• Cervicitis in women
• Proctitis
• Pelvic inflammatory disease
• Sexual contacts of confirmed M. genitalium cases 2

Testing is NOT recommended for asymptomatic individuals, including pregnant women without exposure history 2.